CI

$262.84-1.73 (-0.65%)

Market ClosedAs of Mar 20, 8:00 PM UTC

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$262.84
Potential Upside
72.2%
Whystock Fair Value$452.60
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealthcare Plans

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy b...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$70.21B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.85
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
12.03%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
-

Recent News

Motley Fool
Mar 20, 2026

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Mar 20, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Mar 20, 2026

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 16, 2026

Bernstein Upgrades The Cigna Group (CI) From “Market Perform” to “Outperform”

The Cigna Group (NYSE:CI) stands among the 11 best very cheap stocks to buy according to billionaires. On March 12, 2026, The Cigna Group (NYSE:CI) drew attention from analysts at Bernstein. The firm’s analysts expect the stock’s multiple to increase over time, citing the combination of the Pharmacy Benefit Manager reform bill and the FTC […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 13, 2026

The Bull Case For Cigna Group (CI) Could Change Following CEO Succession To Brian Evanko – Learn Why

The Cigna Group has announced that long-time CEO David M. Cordani will retire from the role on July 1, 2026, transitioning to executive chair while current president and COO Brian Evanko becomes chief executive officer and joins the board. This planned leadership handover, featuring a successor with deep experience across Cigna Healthcare, Evernorth Health Services, and finance, signals an emphasis on continuity in data-driven, technology-enabled healthcare services. We’ll now examine how...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.